Chemed Corporation CHE R3KPHARMA

Q: What is the current share price of Chemed Corporation (CHE)?

As of 2026-09-19 21:16 PDT, Chemed Corporation (CHE) trades at $519.01 on NYSE. Its 52-week range is $367.60 to $551.99.

Q: What is the market capitalisation of CHE?

Chemed Corporation (CHE) has a market capitalisation of $6.78B on NYSE.

Q: What is the P/E ratio of CHE?

CHE trades at a trailing price-to-earnings (P/E) ratio of 26.11. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.13.

Q: Does CHE pay a dividend?

Chemed Corporation (CHE) currently offers a dividend yield of 0.54%.

Q: What is the return on equity (ROE) of CHE?

CHE has a return on equity (ROE) of 27.11%. Its return on capital employed (ROCE) is 27.04%.

Q: Is CHE a good stock to buy?

This page provides a data-driven analysis of Chemed Corporation (CHE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Care Facilities · United States

https://www.chemed.com

Company Profile ↓

$519.01

+15.71% 1Y

Mkt Cap$6.78B

P/E26.11

P/B8.13

Div. Yield0.54%

52W High$551.99

52W Low$367.60

Book Value$63.81

EPS (TTM)$19.88

Company Overview

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 27.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 27.0%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.35.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $2.53B (+65.3% YoY); net profit $265.24M.
Trailing 12 Months Year-on-year growth — revenue +8.8%, earnings +43.7%.
5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR 8.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	4.75%
1 Year:	8.80%

Compounded Profit Growth

5 Years:	8.40%
1 Year:	43.70%

Stock Price Performance

1 Year:	+15.71%
6 Months:	+28.98%
3 Months:	+18.35%
1 Month:	-5.98%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 82% of range

$367.60 $551.99

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)45.89 · Neutral

Price Performance

1M-5.98%

3M+18.35%

6M+28.98%

1Y+15.71%

Valuation vs Sector

P/E of 26.11 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 27.1%.
Healthy ROCE of 27.0%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

26.11

Industry PE

24.83

Forward P/E

18.86

PEG Ratio

1.90

Book Value

$63.81

Price to Book

8.13

P/S

2.61

EV/EBITDA

16.81

Dividend Yield

0.54%

Growth (CAGR)

Revenue 5Y

4.75%

Profit 5Y

8.40%

Revenue (YoY)

8.80%

Earnings (YoY)

43.70%

Profitability & Returns

ROCE

27.04%

ROE

27.11%

ROA

13.45%

Profit Margin

10.60%

Op Margin

13.25%

Gross Margin

33.11%

EPS (Latest Qtr)

$5.13

EPS (TTM)

$19.88

Balance Sheet & Liquidity

Debt/Equity

0.35

Quick Ratio

0.72

Current Ratio

0.91

Debt

$294.79M

Total Assets

$1.58B

Current Assets

Working Capital

Ownership

Promoter Holding

1.95%

Chg in Prom Hold

0.01%

FII / Inst Holding

106.53%

Chg in FII Hold

0.19%

Financial Snapshot

Enterprise Value

$6.78B

Total Revenue (TTM)

$2.60B

EBITDA

$416.92M

Free Cash Flow

$307.86M

Operating Cash Flow

$389.95M

Shares Outstanding

13.07M

Gross Margin

33.11%

Payout Ratio

12.07%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CHE Chemed Corporation R3KPHARMA	519.01	26.11	$6.78B	0.54%	27.04%	27.11%	4.75%	8.40%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	315.79M	311.94M	317.41M	299.19M	297.78M	296.54M	310.48M	320.86M	333.73M	354.01M	374.56M	391.41M	-	-	-	-	-
Operating Income	25.89M	29.21M	36.65M	41.52M	40.21M	40.57M	44.60M	50.13M	44.39M	38.36M	42.87M	41.45M	-38.95M	54.00M	56.40M	58.14M	61.71M	49.47M	65.53M	64.93M	79.36M	92.76M	74.31M	80.44M	71.70M	92.87M	89.37M	91.94M	80.86M	72.82M	69.51M	86.85M	72.33M	88.12M	92.16M	94.76M	68.08M	74.75M	84.58M	89.20M
Net Income	14.61M	17.43M	20.57M	24.36M	24.59M	24.54M	26.98M	28.83M	24.84M	24.89M	26.83M	29.84M	-21.66M	35.44M	45.00M	54.97M	51.25M	44.67M	50.73M	58.95M	55.89M	82.10M	67.72M	65.40M	56.52M	72.00M	64.17M	66.46M	56.87M	54.12M	53.38M	74.96M	65.02M	70.89M	75.78M	71.76M	52.49M	64.24M	66.30M	67.70M
Diluted EPS	0.77	0.94	1.12	1.36	1.39	1.40	1.55	1.65	1.45	1.48	1.62	1.78	-1.35	2.13	2.66	3.27	3.06	2.70	3.08	3.56	3.38	5.01	4.14	4.01	3.51	4.55	4.22	4.40	3.78	3.58	3.51	4.93	4.24	4.65	5.00	4.86	3.57	4.46	4.84	5.13

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.15B	1.19B	1.28B	1.36B	1.43B	1.41B	1.46B	1.54B	1.58B	1.67B	1.20B	1.28B	1.33B	1.26B	1.20B	1.32B	1.53B	2.53B
Operating Income	132.86M	126.34M	143.52M	153.73M	156.42M	133.39M	168.42M	184.46M	178.75M	113.03M	243.63M	257.38M	389.68M	343.04M	343.50M	340.57M	366.49M	338.25M
Net Income	67.28M	73.78M	81.83M	85.98M	89.30M	77.23M	99.32M	110.27M	108.74M	98.18M	205.54M	219.92M	319.47M	268.55M	249.62M	272.51M	302.00M	265.24M
Diluted EPS	2.88	3.24	3.55	4.10	4.62	4.16	5.57	6.33	6.48	5.86	12.23	13.31	19.48	16.85	16.53	17.93	19.89	18.34

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	819.47M	830.16M	795.90M	859.63M	893.70M	859.93M	852.33M	880.06M	920.03M	975.53M	1.27B	1.43B	1.34B	1.44B	1.67B	1.67B	1.54B
Total Equity	395.80M	396.83M	477.16M	462.05M	413.68M	453.29M	448.89M	451.36M	513.25M	524.10M	540.35M	591.33M	726.61M	901.20M	623.27M	798.72M	1.11B	1.12B	979.40M
Cash & Equivalents	4.99M	3.63M	112.42M	49.92M	38.08M	69.53M	84.42M	14.13M	14.73M	15.31M	11.12M	4.83M	6.16M	162.68M	32.90M	74.13M	263.96M	178.35M	74.52M
Long Term Debt	-	-	152.13M	159.21M	166.78M	174.89M	183.56M	141.25M	83.75M	100.00M	91.20M	89.20M	90.00M	-	185.00M	92.50M	-	-	-
Total Liabilities	-	-	342.31M	368.11M	382.22M	406.33M	444.81M	408.58M	339.07M	355.96M	379.67M	384.19M	541.71M	533.71M	719.45M	643.30M	560.22M	549.58M	558.78M
Current Liabilities	-	-	136.08M	149.34M	145.40M	156.82M	363.99M	175.55M	171.34M	171.83M	193.52M	191.67M	262.22M	299.11M	302.40M	297.20M	312.05M	285.69M	287.13M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	112.08M	160.83M	86.01M	174.34M	131.77M	-	-	171.50M	135.39M	162.50M	287.14M	301.25M	489.29M	-	309.89M	330.30M	417.50M	388.27M
Investing Cash Flow	-28.63M	-22.84M	-35.70M	-34.11M	-40.68M	-31.35M	-	-50.32M	-39.86M	-67.61M	-105.22M	-190.76M	-61.56M	-	-59.40M	-60.64M	-143.91M	-59.34M
Financing Cash Flow	-84.82M	-29.20M	-112.81M	-152.06M	-59.63M	-104.61M	-	-120.59M	-94.95M	-99.08M	-188.20M	-109.16M	-271.21M	-	-209.25M	-79.83M	-359.19M	-432.77M
Capital Expenditure	-26.09M	-21.50M	-25.64M	-29.59M	-35.25M	-29.32M	-43.57M	-44.13M	-39.77M	-64.30M	-52.87M	-53.02M	-58.83M	-	-57.33M	-56.85M	-49.53M	-62.80M
Free Cash Flow	85.99M	139.34M	60.37M	144.75M	96.52M	-	-	127.36M	95.62M	98.19M	234.27M	248.23M	430.46M	-	252.56M	273.44M	367.97M	325.48M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41.23M	189.83M	-85.61M	-103.83M
Share Buybacks	67.12M	742.00K	109.33M	143.97M	60.62M	92.91M	110.02M	59.32M	102.31M	94.64M	158.88M	92.63M	175.59M	576.04M	114.52M	67.70M	361.39M	431.50M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	11.6%	10.6%	11.2%	11.3%	10.9%	9.4%	11.6%	12.0%	11.3%	6.8%	20.3%	20.1%	29.2%	27.2%	28.6%	25.9%	23.9%	13.4%
Net Margin %	5.9%	6.2%	6.4%	6.3%	6.2%	5.5%	6.8%	7.1%	6.9%	5.9%	17.2%	17.2%	23.9%	21.3%	20.8%	20.7%	19.7%	10.5%
ROE %	17.0%	15.5%	17.7%	20.8%	19.7%	17.2%	22.0%	21.5%	20.7%	18.2%	34.8%	30.3%	35.4%	43.1%	31.3%	24.6%	27.0%	27.1%
ROCE %	-	18.5%	21.1%	23.6%	22.3%	25.2%	24.6%	27.1%	25.2%	15.6%	31.1%	25.6%	34.3%	33.0%	30.0%	25.1%	26.5%	27.0%

Shareholding Pattern

Insiders

1.95%

Institutions

106.53%

Public Float

108.64%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	11.36%	1.48M	$748.17M
2	AQR Capital Management, LLC	7.44%	972.47K	$490.19M
3	Vanguard Portfolio Management LLC	6.02%	787.07K	$396.73M
4	Vanguard Capital Management LLC	4.62%	604.42K	$304.66M
5	Acadian Asset Management. LLC	3.47%	453.24K	$228.46M
6	State Street Corporation	3.40%	444.72K	$224.16M
7	Geode Capital Management, LLC	3.17%	413.94K	$208.65M
8	JPMORGAN CHASE & CO	3.09%	403.39K	$203.34M
9	Boston Partners	2.15%	280.68K	$141.48M
10	Epoch Investment Partners, Inc.	2.05%	267.29K	$134.73M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CHE

Google News Mon, 07 Sep 2026

Chemed Corp (CHE) Stock Analysis: Navigating Healthcare with Strong Revenue Growth and a 6% Upside Potential - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQaEJtSHBLX1ZUT3RLSG5laVJ6OE41Q3dlU21BZXJCbGxaQzVjTC02Q0RGd0VWMmh1dkIyWl9nUFE2OEZEZThWMk40ejBoZTJpMXAyZi1iLUxSZlBVRXZ1R3Y1ZUQyN25uQllzaGRaVmlPQ1FfOUFvM1dHeU1ibUFGc0szNlg4QWxJSmZoa3…

Google News ue, 25 Aug 2026

OPCH or CHE: Which Is the Better Value Stock Right Now? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOdGNsNFVVOUFKWDdCRE5jdzE2bkhyWXc4MlhhaTJ0bTBFQ21ZdTU0czI0SGJuOEtMb0prQ3haZEtzMmI5WDZRUENVdm0zWG4zSndySnpUNGpMb1k4LVpqVERXbzNJb2VzWW1ITGFSTUNUbnh2OC1VaVh0MWVjR1pIaWFzOGFpUWExTE9YNj…

Google News Mon, 07 Sep 2026

Public Employees Retirement System of Ohio Makes New Investment in Chemed Corporation $CHE - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVF9Eb3I2LXREeXA0aG5EVFRNeFhrNUZSR3FDNlRXME1UUmVyZnZjUzJNV1lHSjcwMGlQTXIyeFBlQVlZdXVTbWt0U3MySmV6djFsekhvRUduSm9mSHh2bGZWakdXekNrSXI0OVMzUU92OEV1RTViQ1ZEcXBnQkFQZGE5dlVPUWdQZG53MT…

Google News hu, 27 Aug 2026

Why Chemed (CHE) Stock Is Down Today - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5ZSDhob19YU2NtbG1DbFJ2MmtZd0QzVzVEZ3B0SEdoSlJzLWdQd25od05yZU1DSHRRZUhmLXYzMnR3YURIQkZNV3NkeC1vUTIyNHctZmJ4c0RFODFQV0VHUzYyQkgyNWYzTDU0UG5Ba2RobUhwSUxwSHFiTEFCdw?oc=5" target="_blan…

Google News Sat, 05 Sep 2026

(CHE.DB.E) Daily Stock Insights (CHE.DB.E:CA) - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOVzNCamxGVFpnTGpHU21XeVFZOGxwM3NsVW9yclBRQkxoQ2lpeGZwemJVVk9lVFNRZHZ3c0ctR0I2bGpob3k4NjJGdnRMU2dNRjk3ZnFodnREeTN6SFJBTjBCbFpaR1ZRYllfd2VyRXBKZGRaUWkxT1hNTTh6cUY0WEthY3BvMndObl9yWX…

Google News hu, 23 Apr 2026

Chemed’s (NYSE:CHE) Q1 CY2026 Sales Top Estimates, Stock Jumps 10.2% - StockStory

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOX1ViU2QwOEtNaUQ2YTA4cFpORTFKTWNNdGlfZjJZcVJ1YW5sWkNPZW43d1ZyYXFkNnBDd0RXX0FtUUYzdk1BRzVINC1mTDAzZTc0aWhRb3JjNmpNb2tYM25kNjVJeGlDVXVpRV9ZbVktelYwSEJvYy1taEtoZkxOZXJzT2didEpYWWNFQz…

CHE — Frequently Asked Questions

What is the current share price of Chemed Corporation (CHE)?

As of 2026-09-19 21:16 PDT, Chemed Corporation (CHE) trades at $519.01 on NYSE. Its 52-week range is $367.60 to $551.99.

What is the market capitalisation of CHE?

Chemed Corporation (CHE) has a market capitalisation of $6.78B on NYSE.

What is the P/E ratio of CHE?

CHE trades at a trailing price-to-earnings (P/E) ratio of 26.11. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.13.

Does CHE pay a dividend?

Chemed Corporation (CHE) currently offers a dividend yield of 0.54%.

What is the return on equity (ROE) of CHE?

CHE has a return on equity (ROE) of 27.11%. Its return on capital employed (ROCE) is 27.04%.

Is CHE a good stock to buy?

This page provides a data-driven analysis of Chemed Corporation (CHE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Chemed Corporation CHE R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Chemed Corp (CHE) Stock Analysis: Navigating Healthcare with Strong Revenue Growth and a 6% Upside Potential - directorstalkinterviews.com

OPCH or CHE: Which Is the Better Value Stock Right Now? - finance.yahoo.com

Public Employees Retirement System of Ohio Makes New Investment in Chemed Corporation $CHE - marketbeat.com

Why Chemed (CHE) Stock Is Down Today - Quiver Quantitative

(CHE.DB.E) Daily Stock Insights (CHE.DB.E:CA) - Stock Traders Daily

Chemed’s (NYSE:CHE) Q1 CY2026 Sales Top Estimates, Stock Jumps 10.2% - StockStory

CHE — Frequently Asked Questions

What is the current share price of Chemed Corporation (CHE)?

What is the market capitalisation of CHE?

What is the P/E ratio of CHE?

Does CHE pay a dividend?

What is the return on equity (ROE) of CHE?

Is CHE a good stock to buy?

Explore More